Glioblastoma adaptive global innovative learning environment
Brief description of study
This research study aims to evaluate multiple investigational treatments for either newly diagnosed or recurrent brain tumors to determine if any of these study treatment(s) improve overall survival as compared to standard treatments.
The investigational drugs that will be used in this research study are temozolomide for newly diagnosed glioblastoma and Lomustine for recurrent glioblastomas.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
-
Conditions:
Glioblastoma
-
Age: Between 18 Years - 99 Years
-
Gender: All
Updated on
09 Mar 2024.
Study ID: 834751
If you need assistance finding a non-cancer clinical research study or if you have any questions, please email psom-ocr@pobox.upenn.edu
For cancer trials contact EmergingMed: 1-855-216-0098 or PennCancerTrials@emergingmend.com
